Increasing R&D Investments in discovering Effective Therapeutics for Lung Cancer to Drive the Non-Small Cell Lung Cancer (NSCLC) Market

According to a recent research report published by MarkNtel Advisors, the Global Non-Small Cell Lung Cancer (NSCLC) Market is expecting around 11.2% CAGR during 2022-27. The exponentially rising prevalence of lung cancers, especially NSCLC, across different corners of the world, i.e., augmenting the demand for their effective diagnosis & treatments and instigating governments of various countries to invest substantially in the healthcare infrastructure, is the prime aspect driving the global market.

Moreover, the growing necessity to cater to the high unmet needs of patients, i.e., instigating biopharma firms to bring innovations in existing therapeutics & introduce novel drugs for lung cancer treatments, is further boosting the Global Non-Small Cell Lung Cancer (NSCLC) Market.

Besides, increasing awareness among people about the easy availability of several diagnoses & treatments through various government campaigns, advertisements, etc., are also fueling the patient pool for NSCLC globally and, in turn, positively influencing the market growth, further states the research report, “Global Non-Small Cell Lung Cancer (NSCLC) Market Analysis, 2022.”

High Efficacy of Immunotherapy Drugs to Boost the Global Market

Immunotherapy is likely to significantly contribute to the worldwide expansion of the Non-Small Cell Lung Cancer (NSCLC) Market during 2022-27. It owes principally to the increasing number of patients with NSCLC & their growing awareness about the benefits of immunotherapy drugs like enhanced efficacy & safety that strengthen & direct the immune system of the body to detect & kill the cancer cells effectively.

Immune checkpoint inhibitors turn the immune system on to target the cancer cells directly & attack potentially harmful agents in the body. The most extensively used immune checkpoint inhibitors in immunotherapy include PD-1, PD-L1, & Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4).

With Massive Healthcare Expenditure, North America Dominates the Market

Geographically, North America holds the largest share in the Non-Small Cell Lung Cancer (NSCLC) Market, principally due to the massive healthcare expenditure by governments of different countries toward introducing novel NSCLC medications and procuring more diagnosis equipment & drugs to cater to the unmet needs of patients.

Since the US is witnessing a massive patient pool for NSCLC, the leading biopharma companies in the country are showcasing collaborations, mergers & acquisitions, and partnerships to expand their visibility & product portfolios. Hence, is is another prominent aspect projecting lucrative prospects for the North America Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

Competitive Landscape

The major companies in the Global Non-Small Cell Lung Cancer (NSCLC) Market include Allergan (AbbVie), AstraZeneca PLC., Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline PLC., F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Sanofi S.A.

Key Questions Answered in the Research Report

1. What are the current & future trends in the Global Non-Small Cell Lung Cancer (NSCLC) Market?
2. How has the industry been evolving in terms of geography & product adoption?
3. How has the competition been shaping across various countries, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Non-Small Cell Lung Cancer (NSCLC) Market?
5. What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Non-Small Cell Lung Cancer (NSCLC) Market?

Market Segmentation:

1. By Diagnosis (Blood & Urine Tests, Imaging, Biopsy, Sputum Cytology, Bronchoscopy)
2. By Cancer Type (Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), Adenocarcinoma)
3. By Treatment (Surgery, Chemotherapy, Immunotherapy (Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitor)), Radiation Therapy (External Beam Radiation Therapy, Brachytherapy (Internal Radiation Therapy)), Radiofrequency Ablation (RFA), Targeted Therapy)
4. By End-User (Hospitals, Cancer Centers, Others (Ambulatory Surgery Centers, etc.))
5. By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)
6. By Country (The US, Canada, Mexico, Brazil, the UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)